Facebook      Twitter

blank

blank

ONLINE LEARNING CENTER
 

Metabolic Complications Associated with the Treatment of HIV-Infected Persons (10HC02)

Mark J. Fussa, DO and Sindy M. Paul, MD, MPH, FACPM

 
 
 
 

Release Date: June 30, 2008
Review Date: December 22, 2009
Expiration Date: EXPIRED December 31, 2010
Activity Code: 10HC02-DE02

CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY.
Content is provided for informational purposes only.



If you have any questions about this process, please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.

As seen in the June 2008 edition of


ACTIVITY INFORMATION

Sponsor

Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), UMDNJ-Center for Continuing & Outreach Education. This activity is supported by an educational grant from NJDHSS Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”

Grantor Acknowledgement

This activity is supported by an educational grant from NJDHSS Division of HIV/AIDS Services through a MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”

Target Audience

This activity is designed for physicians and nurses, and for other health care professionals in New Jersey who are involved in the care of persons with HIV/AIDS.

Statement of Need

The medical management of HIV has been revolutionized by the use of highly active antiretroviral therapy (HAART). In the pre-HAART era, HIV typically led to death within ten years. Treatment of HIV with HAART can extend the lifespan of HIV-infected persons several decades. A major challenge that has arisen out of this success is the management of the side effects of antiretroviral therapy. Antiretroviral therapy (ART) commonly causes various complications, some of which may be life threatening.

Abnormalities such as dyslipidemia, insulin resistance states, and lipodystrophy syndromes have become common metabolic complications associated with the treatment of HIV-infected persons, and may eventually lead to an epidemic of cardiovascular disease and diabetes among HIV-infected patients. Management of these complications has therefore become an integral component of HIV care.

Learning Objectives

Upon completion of this learning activity, the reader should be able to:

  • Describe metabolic complications associated with the use of
    antiretroviral agents.
  • Identify the risks and appropriate management of dyslipidemia for patients
    on antiretroviral agents.
  • Summarize the treatment of glucose intolerance in patients on
    antiretroviral agents.
  • Describe lipodystrophy and its management in patients on antiretroviral
    agents

Method of Instruction

Participants should read the learning objectives and review the activity in its entirety. After reviewing the material, complete the post-test which consists of a series of multiple-choice and True/False questions.

Upon completing this activity as designed and achieving a passing score of 70% or more on the post-test, participants will have access to a printable online credit statement. Estimated time to complete this activity as designed is 1.25 hours.

Accreditation

EXPIRED- CE is no longer available for this activity. This content is being provided for informational purposes only.

Physicians:
UMDNJ–Center for Continuing and Outreach Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.25 hours of AMA PRA category 1 credit™. Each physician should claim only those credits that he/she actually spent in the activity.

Nurses:
UMDNJ-Center for Continuing & Outreach Education is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is awarded 1.25 contact hours. (60 minute CH.)

Provider approved by the California Board of Registered Nursing, Provider Number CEP 13780.

UMDNJ-Center for Continuing and Outreach Education certifies that this continuing education offering meets the criteria for up to 0.125 Continuing Education units (CEU's). One CEU equals 10 contact hours of participation.

Review

This activity was peer reviewed for relevance, accuracy of content, and balance of presentation by Patricia Kloser, MD, MPH; and Brenda Christian, MEd, PA-C; and pilot tested for relevance and time required for participation by Kinshasa Morton, MD; Bonnie Abedini, RN, MSN; Linda Berezny, RN, BA; and Mary C. Krug, RN, MSN, APN-C.

Faculty

Mark J. Fussa, DO, is an Infectious Diseases Fellow with Garden State Infectious Diseases Associates, under the auspices of UMDNJ-SOM. He recently completed a Public Health Rotation with the NJ Dept. of Health and Senior Services, Division of HIV/AIDS Services.

Sindy M. Paul, MD, MPH, FACPMP, is the Medical Director of the NJ Dept. of Health and Senior Services, Division of HIV/AIDS Services; Assistant Clinical Professor at the University of Medicine & Dentistry of New Jersey (UMDNJ); and past President, New Jersey Board of Medical Examiners.

Case reports:

Patricia C. Kloser, MD, MPH, FACP, is Professor of Medicine and Preventive Medicine and Public Health, UMDNJ-New Jersey Medical School and School of Public Health; and Medical Director, Division of AIDS Education, UMDNJ-Center for Continuing & Outreach Education.

Debbie Y. Mohammed, MS, MPH, APRN-BC, AACRN, is an Advanced Practice Nurse, providing care and treatment to PLWHA and is Project Director for Targeted Rapid HIV Testing at University Hospital, Newark.

Faculty Disclosure Declarations

The following have no financial relationships to disclose:
FACULTY: Mark J. Fussa, DO and Sindy M. Paul, MD, MPH, FACPM
REVIEWERS: Patricia Kloser, MD, MPH; Brenda Christian, MEd, PA-C; Kinshasa Morton, MD; Bonnie Abedini, BSN, MS; Linda Berezny, RN, BA; and Mary C. Krug, RN, MSN, APN-C; and New Jersey AIDSLine editor Kimi Nakata, MSW, MPH.

Off-Label Usage Disclosure

This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Disclaimer

The views expressed in this activity are those of the faculty.It should not be inferred or assumed that they are expressing the views of NJDHSS-Division of HIV/AIDS Services, UMDNJ, or any manufacturer of pharmaceuticals.The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Copyright© 2008 UMDNJ-Center for Continuing & Outreach Education. All rights reserved including translation into other languages.No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission inwriting from UMDNJ-Center for Continuing & Outreach Education.


 

 

© Copyright 2014, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy